The company said revenue for Q3 2026 grew 11% year-over-year on a reported basis to $1.344 billion, up from $1.209 billion in Q3 2025. It said U.S. revenue grew 14% and international revenue grew 5%.

1. 01

   The company said revenue for Q3 2026 grew 11% year-over-year on a reported basis to $1.344 billion, up from $1.209 billion in Q3 2025. It said U.S. revenue grew 14% and international revenue grew 5%.

2. 02

   DexCom said GAAP operating income for Q3 2026 was $327.2 million (24.3% of revenue), up 420 basis points from $242.5 million (20.1%) in Q3 2025. Non-GAAP operating income was $339.5 million (25.3%).

3. 03

   The company said it set its 2026 full-year revenue outlook at $5.20 to $5.25 billion (approximately 12 to 13% growth) and raised the midpoint of that outlook. Its board authorized a share repurchase program of up to $1.0 billion through December 31, 2027.

4. 04

   Dexcom said GAAP net income for Q3 2026 was $275.1 million ($0.72 per diluted share), compared with $283.8 million ($0.70) in Q3 2025. As of September 30, 2026, it held $1.82 billion in cash, cash equivalents and marketable securities.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.